Warning Letter Walkthrough: Making Monitoring, Site Activation Top Priorities

A recent FDA Warning Letter illustrates to sponsors the importance of properly managing monitoring responsibilities and having a thorough site activation process. In this article, we’ll examine the letter received by the sponsor of a multisite trial of a device for preventing recurrent ischemic stroke and discuss how problems could have been avoided in the first place.
Source: Drug Industry Daily